Stories

Bloomberg-funded tobacco control is facing renewed scrutiny at the same time the latest GSTHR report shows a global shift towards safer nicotine use. That contrast matters: billions can be spent resisting products that consumers are already using to move away from cigarettes. Public health should be accountable not only for its intentions, but for whether its influence helps reduce smoking or keeps harm reduction politically inconvenient.

Laboratory data can tell us what a product emits; real-world use tells us how it actually fits into people’s lives. Evidence on blu should therefore be judged not only by product chemistry, but by switching patterns, user behaviour and whether smokers move away from cigarettes completely. That is where harm reduction becomes measurable. The most useful question is not whether a vaping product is perfect, but whether it reduces exposure for adults who would otherwise keep smoking.

Half a billion dollars to fight a collapsing trend deserves scrutiny. Youth vaping has fallen sharply, yet lawmakers are still treating it as an expanding emergency while adult smoking remains the bigger driver of preventable disease. Resources should follow the scale of harm, not the politics of alarm. Serious nicotine policy would protect young people without using outdated crisis language to justify measures that may also make quitting harder for adults.

The phrase “vaping is worse than smoking” does more than misstate the evidence — it changes behaviour. A smoker who believes that message may see little reason to switch, even though cigarettes remain the far more harmful product. Good fact-checking restores the missing hierarchy: vaping is not harmless, but it is not smoking. Clear risk communication can be the difference between staying with combustion and taking a less harmful route away from it.

A smoking rate is only as reliable as the data behind it. Australia’s 5.8% figure raises questions about what is being counted, what may be missed and how illicit tobacco use affects the picture. A low number can shape policy confidence, media narratives and international reputation, so the methods matter. Before Australia is held up as a success story, its smoking data needs to match the reality of the market.

Malaysia’s vape ban debate should raise concern for anyone focused on outcomes rather than appearances. Removing legal access to lower-risk products can push consumers towards illicit supply, reduce oversight and leave adult smokers with cigarettes as the more stable option. Youth protection deserves strong enforcement, but broad bans often weaken the very safeguards they claim to create. A better approach would regulate vaping responsibly while keeping the route away from combustion open.

The safer nicotine option should be the easier option. That principle is simple, but many policies still do the opposite by keeping cigarettes familiar, affordable or accessible while making lower-risk alternatives harder to find or understand. Adult smokers need a path away from combustion that is practical in the real world, not only acceptable in theory. Harm reduction works best when regulation makes the less harmful choice the obvious one.

Nicotine pouch testing should be driven by science, not suspicion by category. Better data on ingredients, emissions, exposure and product performance can help regulators distinguish between responsible smoke-free products and those that fail basic standards. That matters because credible harm reduction depends on transparency as much as access. The stronger the testing framework, the harder it becomes to dismiss pouches with fear — or to defend products that do not meet the evidence.

Tobacco control can end up protecting cigarettes even when that is the opposite of its intention. Policies that restrict or stigmatise lower-risk nicotine alternatives may leave combustible tobacco with less competition and adult smokers with fewer viable exits. That is the uncomfortable contradiction at the heart of many anti-vaping campaigns. Public health should scrutinise industry influence, but it should also ask whether its own strategies are keeping the most harmful product in the strongest position.

Tobacco control embracing harm reduction would mark a shift from fighting nicotine use in the abstract to reducing the harms that actually kill. FDA vaping policy should recognise that adult smokers need legal, evidence-based alternatives capable of moving them away from combustion. That does not weaken prevention or youth protection; it makes the overall strategy more realistic. Public health progress depends on helping people stop smoking, not on treating every nicotine product as the same threat.